Latest Sangamo Biosciences (SGMO) Headlines
Watch These 3 High-Risk Stocks
at The Street - Tue Mar 11, 8:27AM CDT
Chris Lau, Kapitall: These high-risk stocks have made big moves. Is it time for you to make a move? High-risk [...]
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
What You Need to Know About Sangamo Biosciences' Surge
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:00PM CDT
Sangamo Biosciences' promising early stage HIV drug SB-728-T may someday change how doctors treat patients. Results from a small, 14 person phase 1 trial suggest that while the drug doesn't eradicate HIV from patients, it may someday offer patients...
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Sangamo Soars on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 10:50AM CST
Sangamo's HIV candidate SB-728-T has shown great promise.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Sangamo Biosciences (SGMO) Worth Watching: Stock Surges 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:25AM CST
Sangamo Biosciences was a big mover last session, as the company saw its shares rise just over 17% on the day.
Top Gainers Pre-Market Notes: Pixelworks, Yingli Green Energy Holding, McDermott Intl., and Sangamo Biosciences
PR Newswire - Fri Mar 07, 7:00AM CST
The US markets saw a mixed sentiment on Thursday, March 06, 2014, with the NASDAQ Composite closing at 4,352.13, down 0.13%, the Dow Jones Industrial Average ending the session at 16,421.89, up 0.38% and the S&P 500 edging 0.17% higher to finish the trading session at 1,877.03. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Consumer Staples and Utilities sectors. A number of stocks saw large movements, including Pixelworks Inc. (NASDAQ: PXLW), Yingli Green Energy Holding Company Ltd (NYSE: YGE), McDermott International Inc. (NYSE: MDR), and Sangamo BioSciences Inc. (NASDAQ: SGMO), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
Jim Cramer's Top Stock Picks: TSLA SCTY SGMO CSX PF
at The Street - Fri Mar 07, 5:00AM CST
Sangamo BioSciences could one day cure a lot of diseases and Pinnacle Foods is one of Cramer's favorite food companies.
Jim Cramer's 'Mad Money' Recap: How to Value a Stock
at The Street - Thu Mar 06, 7:08PM CST
There are many ways to do so, and sticking to just one will cost you money, Cramer warns.
Why Sangamo Biosciences, Inc. Trounced the Market
David Williamson, The Motley Fool - Motley Fool - Thu Mar 06, 6:38PM CST
Shares of Sangamo Biosciences are up more than 20% today on the news that HIV patients who were given Bristol-Myers Squibb 's drug Cytoxan responded better to Sangamo's drug SB-728-T, which is made up of the patient's own genetically modified...
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Look for Shares of Sangamo Biosciences to Potentially Pullback after Yesterday's 17.08% Rise
Comtex SmarTrend(R) - Thu Mar 06, 4:26PM CST
Sangamo Biosciences (NASDAQ:SGMO) traded in a range yesterday that spanned from a low of $21.76 to a high of $24.12. Yesterday, the shares gained 17.1%, which took the trading range above the 3-day high of $19.65 on volume of 11.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Staples and SodaStream are big market movers
AP - Thu Mar 06, 3:25PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
4 Huge Stocks on Traders' Radars
at The Street - Thu Mar 06, 2:08PM CST
Here's a look at how to trade some of the most active stocks on the market today.
Why Sangamo Biosciences Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:39PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sangamo Biosciences , a clinical-stage...
Sangamo Presents Clinical Data At CROI 2014 Demonstrating Enhancement Of SB-728-T Engraftment - Continued Control Of HIV Viral Load For 31 Weeks Without ART In SB-728-T Treated Subject
PR Newswire - Thu Mar 06, 11:16AM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6, 2014 issue of the New England Journal of Medicine (NEJM).
Sangamo climbs on early results for HIV therapy
AP - Thu Mar 06, 10:16AM CST
NEW YORK (AP) — Shares of Sangamo BioSciences jumped Thursday after it reported positive clinical trial results for an experimental HIV treatment.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Watch These 3 High-Risk Stocks
at The Street - Tue Mar 11, 8:27AM CDT
Chris Lau, Kapitall: These high-risk stocks have made big moves. Is it time for you to make a move? High-risk [...]
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
What You Need to Know About Sangamo Biosciences' Surge
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:00PM CDT
Sangamo Biosciences' promising early stage HIV drug SB-728-T may someday change how doctors treat patients. Results from a small, 14 person phase 1 trial suggest that while the drug doesn't eradicate HIV from patients, it may someday offer patients...
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Sangamo Soars on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 10:50AM CST
Sangamo's HIV candidate SB-728-T has shown great promise.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Sangamo Biosciences (SGMO) Worth Watching: Stock Surges 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:25AM CST
Sangamo Biosciences was a big mover last session, as the company saw its shares rise just over 17% on the day.
Top Gainers Pre-Market Notes: Pixelworks, Yingli Green Energy Holding, McDermott Intl., and Sangamo Biosciences
PR Newswire - Fri Mar 07, 7:00AM CST
The US markets saw a mixed sentiment on Thursday, March 06, 2014, with the NASDAQ Composite closing at 4,352.13, down 0.13%, the Dow Jones Industrial Average ending the session at 16,421.89, up 0.38% and the S&P 500 edging 0.17% higher to finish the trading session at 1,877.03. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Consumer Staples and Utilities sectors. A number of stocks saw large movements, including Pixelworks Inc. (NASDAQ: PXLW), Yingli Green Energy Holding Company Ltd (NYSE: YGE), McDermott International Inc. (NYSE: MDR), and Sangamo BioSciences Inc. (NASDAQ: SGMO), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
Jim Cramer's Top Stock Picks: TSLA SCTY SGMO CSX PF
at The Street - Fri Mar 07, 5:00AM CST
Sangamo BioSciences could one day cure a lot of diseases and Pinnacle Foods is one of Cramer's favorite food companies.
Jim Cramer's 'Mad Money' Recap: How to Value a Stock
at The Street - Thu Mar 06, 7:08PM CST
There are many ways to do so, and sticking to just one will cost you money, Cramer warns.
Why Sangamo Biosciences, Inc. Trounced the Market
David Williamson, The Motley Fool - Motley Fool - Thu Mar 06, 6:38PM CST
Shares of Sangamo Biosciences are up more than 20% today on the news that HIV patients who were given Bristol-Myers Squibb 's drug Cytoxan responded better to Sangamo's drug SB-728-T, which is made up of the patient's own genetically modified...
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Look for Shares of Sangamo Biosciences to Potentially Pullback after Yesterday's 17.08% Rise
Comtex SmarTrend(R) - Thu Mar 06, 4:26PM CST
Sangamo Biosciences (NASDAQ:SGMO) traded in a range yesterday that spanned from a low of $21.76 to a high of $24.12. Yesterday, the shares gained 17.1%, which took the trading range above the 3-day high of $19.65 on volume of 11.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Staples and SodaStream are big market movers
AP - Thu Mar 06, 3:25PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
4 Huge Stocks on Traders' Radars
at The Street - Thu Mar 06, 2:08PM CST
Here's a look at how to trade some of the most active stocks on the market today.
Why Sangamo Biosciences Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:39PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sangamo Biosciences , a clinical-stage...
Sangamo Presents Clinical Data At CROI 2014 Demonstrating Enhancement Of SB-728-T Engraftment - Continued Control Of HIV Viral Load For 31 Weeks Without ART In SB-728-T Treated Subject
PR Newswire - Thu Mar 06, 11:16AM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6, 2014 issue of the New England Journal of Medicine (NEJM).
Sangamo climbs on early results for HIV therapy
AP - Thu Mar 06, 10:16AM CST
NEW YORK (AP) — Shares of Sangamo BioSciences jumped Thursday after it reported positive clinical trial results for an experimental HIV treatment.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
